Skip to content
lifestyle.californiaconsumerbanking.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
NOVO NORDISK INC.
Novo and Hengrui Pharma enter exclusive license agreement for once-weekly oral GLP-1/GIP dual receptor agonist HRS-1596
September 29, 2026
Novo’s denecimig demonstrates tolerability after switch from emicizumab in FRONTIER5 study of people with hemophilia A as published in the Journal of Thrombosis and Haemostasis
September 17, 2026
New Copenhagen facility to strengthen Europe’s quantum manufacturing capabilities
September 4, 2026
Novo Nordisk’s Awiqli®, the first once-weekly basal insulin for adults with type 2 diabetes, now available in the US
August 11, 2026
Novo Nordisk takes action to stop multiple misleading national GLP-1 advertising campaigns by Eli Lilly
July 21, 2026
Novo Nordisk’s denecimig (Mim8) demonstrated positive results in long term safety and efficacy in phase 3 hemophilia A FRONTIER extension study at ISTH 2026
July 11, 2026
No easy answers: European research consortia take on major challenges
July 10, 2026
Wegovy® is now accessible to eligible Medicare beneficiaries living with obesity through Medicare GLP-1 Bridge
July 1, 2026
Novo Nordisk to showcase new data across its hemophilia portfolio at the ISTH Congress 2026, featuring investigational denecimig
June 26, 2026
New European initiative to accelerate drug discovery for cardiometabolic diseases
June 19, 2026
1
2
Next Page
→